rs184561703
Variant summary
Our verdict is Benign. The variant received -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_152792.4(ASPRV1):c.-158C>T variant causes a 5 prime UTR premature start codon gain change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000409 in 1,612,802 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_152792.4 5_prime_UTR_premature_start_codon_gain
Scores
Clinical Significance
Conservation
Publications
- ichthyosis, lamellar, autosomal dominantInheritance: AD Classification: STRONG, MODERATE Submitted by: PanelApp Australia, G2P, Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -8 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| ASPRV1 | ENST00000320256.6 | c.-158C>T | 5_prime_UTR_premature_start_codon_gain_variant | Exon 1 of 1 | 6 | NM_152792.4 | ENSP00000315383.5 | |||
| ENSG00000293615 | ENST00000419542.6 | c.95C>T | p.Pro32Leu | missense_variant | Exon 6 of 6 | 5 | ENSP00000520552.1 | |||
| ASPRV1 | ENST00000320256.6 | c.-158C>T | 5_prime_UTR_variant | Exon 1 of 1 | 6 | NM_152792.4 | ENSP00000315383.5 |
Frequencies
GnomAD3 genomes AF: 0.0000460 AC: 7AN: 152172Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000720 AC: 18AN: 249932 AF XY: 0.0000518 show subpopulations
GnomAD4 exome AF: 0.0000404 AC: 59AN: 1460512Hom.: 0 Cov.: 33 AF XY: 0.0000441 AC XY: 32AN XY: 726420 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000460 AC: 7AN: 152290Hom.: 0 Cov.: 32 AF XY: 0.0000537 AC XY: 4AN XY: 74466 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Inborn genetic diseases Uncertain:1
The c.95C>T (p.P32L) alteration is located in exon 1 (coding exon 1) of the ASPRV1 gene. This alteration results from a C to T substitution at nucleotide position 95, causing the proline (P) at amino acid position 32 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
Prostate cancer Uncertain:1
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at